KRAS and neoplasm: Consistent with KRAS Q61H being a cancer driver in NSCLC, the hotspot variant was clonal and detected in genomic DNA from a tumor relapse obtained 32 months after surgery of the primary tumor (Supplementary Table S1, Supplementary Figure S1).